抑制AEBP1降低了细胞生长和PI3K/AKT通路,同时降低了肝细胞癌中细胞流动性的调节
Liyou Liu1, Qingshan Cai1, Dongyang Wu1
1Department of Hepatobiliary Surgery, Tangshan Central Hospital, No. 601-1 Changning Road, Lubei District, Tangshan, 064000, Hebei Province, China.
脂肪细胞增强剂结合蛋白1 (AEBP1) 通过抑制PI3K/AKT通路,抑制了肝细胞癌 (HCC) 细胞增殖和增加了细胞亡. 尽管AEBP1在侵袭和迁移中的作用有限,但它可能是HCC的治疗目标.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 脂肪细胞增强剂结合蛋白1 (AEBP1) 与原纤维化,细胞外基质调节和瘤性途径有关.
- 在肝细胞癌 (HCC) 中AEBP1的特定作用仍然未被描述.
研究的目的:
- 为了研究AEBP1敲击对HCC细胞增殖,细胞亡,迁移和入侵的影响.
- 阐明AEBP1对HCC中PI3K/AKT信号通路的影响.
主要方法:
- 使用了MHCC-97H和Huh7 HCC细胞系.
- 使用AEBP1 siRNA (siAEBP1) 进行基因淘汰.
- 评估了细胞增殖 (CCK-8,EdU),细胞亡 (TUNEL),入侵 (Transwell),迁移 (划伤试验) 和PI3K/AKT通路激活 (西斑).
主要成果:
- 在两种细胞系中,siAEBP1转染显著降低了AEBP1的表达,抑制了细胞增殖,并诱导了细胞亡.
- 在AEBP1中,低调的p-PI3K/PI3K和p-AKT/AKT表达式.
- 虽然增殖和亡受到了影响,但对入侵和迁移的影响在细胞系之间有所不同.
- 救援实验证实了PI3K/AKT通路的参与.
结论:
- 抑制AEBP1抑制HCC细胞增殖并诱导细胞亡,主要通过PI3K/AKT通路.
- AEBP1显示出作为HCC的治疗点的潜力.
- AEBP1对HCC入侵和迁移的影响似乎取决于背景,并且可能有限.
更多相关视频
11:32Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter
Published on: March 27, 2020
08:50In Vitro Cultivation Techniques for Modeling Liver Organogenesis, Building Assembloids, and Designing Synthetic Tissues using Human Cell Lines
Published on: April 18, 2025
相关概念视频
PI3K/mTOR/AKT Signaling Pathway
Mitogens and the Cell Cycle
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Inhibition of Cdk Activity
cAMP-dependent Protein Kinase Pathways
